COVID Vaccine Developer/Manufacturer Announcements

COVID Vaccine Developer/Manufacturer Announcements
[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

 

AstraZeneca
Press Releases
Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
08 December 2021

 

Bharat Biotech
Press Releases – No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias – [Website not responding at inquiry; receiving 403-Forbidden]

 

CanSinoBIO
News – [Website not responding at inquiry]

Clover Biopharmaceuticals – China
News – No new digest announcements identified
Clover Signs COVID-19 Vaccine Supply Agreement with UNICEF
Dec 7,2021

 

UNICEF signs supply agreement for Clover COVID-19 vaccine
NEW YORK/COPENHAGEN, 7 December 2021 – UNICEF and Clover Biopharmaceuticals Ltd. have signed a long-term agreement for the supply of the Clover COVID-19 vaccine on behalf of the COVAX Facility.
Through the supply agreement, UNICEF will have access to up to 414 million doses of Clover’s COVID-19 vaccine until the end of 2022. These doses were committed to the COVAX Facility through an Advance Purchase Agreement (APA) signed between Gavi, the Vaccine Alliance and Clover Biopharmaceuticals on 30 June 2021. The vaccine will be supplied to participating countries and territories in the COVAX Facility’s Advance Market Commitment (AMC), as well as self-financing participants…

 

Curevac [Bayer Ag – Germany]
News – No new digest announcements identified

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

 

Janssen/JNJ
Press Releases
Dec 09, 2021 United States
World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster

Dec 07, 2021 United States
Janssen Announces Respiratory Syncytial Virus (RSV) Adult Vaccine Candidate Maintains High Efficacy Regardless of Lower Respiratory Tract Disease Severity

Dec 05, 2021 United States
Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses

 

Moderna
Press Releases
December 10, 2021
Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022

December 10, 2021
Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update

 

Novavax
Press Releases – No new digest announcements identified

 

Pfizer
Recent Press Releases
12.09.2021
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older

12.08.2021
Pfizer and BioNTech Provide Update on Omicron Variant

 

Sanofi Pasteur
Press Releases – No new digest announcements identified

 

Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases – No new digest announcements identified

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media
07 December 2021 Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
:: Primary endpoints and secondary endpoints for which data are available were met in trial dominated by COVID-19 variants
:: Efficacy demonstrated against all variants seen in the study, including 75.3% efficacy against COVID-19 of any severity caused by the globally dominant Delta variant
:: Vaccine candidate was well-tolerated, with no related serious adverse events reported in the vaccine group
:: Final regulatory submission to be filed with Health Canada imminently

07 December 2021 Preclinical studies demonstrate sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant

 

Merck
News releases
Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection
December 06, 2021

 

Novartis
News – No new digest announcements identified

 

SK Biosciences
Press releases – No new digest announcements identified

 

Valneva
Press Releases
December 8, 2021
Valneva Signs Advance Purchase Agreement with Bahrain for Inactivated COVID-19 Vaccine VLA2001